Antipsychotic medications and the elderly

Effects on cognition and implications for use

M. J. Byerly, M. T. Weber, D. L. Brooks, L. R. Snow, M. A. Worley, E. Lescouflair

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Despite being frequently prescribed in the elderly, antipsychotic medications are commonly associated with adverse effects in this population, including sedative, orthostatic and extrapyramidal adverse effects. Growing evidence suggests that antipsychotics can also cause deleterious cognitive effects in some elderly patients. Preclinical and growing clinical evidence indicates that inhibitory effects on dopaminergic, cholinergic and histaminergic neurochemical systems may account for antipsychotic-associated cognitive impairment in the elderly. A review of published reports of the cognitive effects of antipsychotics in the elderly suggests that newer antipsychotic medications may possess a more favourable cognitive profile than that of traditional agents in this population. The cognitive effect that a specific antipsychotic will have in the elderly, however, is likely better predicted by considering the pharmacodynamic action of an individual agent in combination with the pathophysiology of the condition being treated. Agents with relatively weak dopamine inhibiting effects (e.g. clozapine and quetiapine), for example, would theoretically have a cognitive profile superior to that of agents with higher degrees of dopaminergic inhibition (all traditional agents, risperidone, olanzapine and ziprasidone) when used for conditions associated with diminished dopamine function (e.g. idiopathic Parkinson's disease). Drugs with weak anticholinergic effects (high-potency traditional agents, risperidone, quetiapine and ziprasidone) would theoretically be less likely to cause cognitive impairment than agents with high degrees of cholinergic receptor blocking actions (clozapine and olanzapine) when treating patients with impaired cholinergic function (e.g. Alzheimer's disease). Cholinergic agonist effects of clozapine and olanzapine may, however, mitigate potential adverse cognitive effects associated with the cholinergic blocking actions of these agents. Large, rigorous trials comparing the cognitive effects of antipsychotics with diverse pharmacodynamic actions are lacking in the elderly and are needed.

Original languageEnglish (US)
Pages (from-to)45-61
Number of pages17
JournalDrugs and Aging
Volume18
Issue number1
StatePublished - 2001

Fingerprint

Cognition
Antipsychotic Agents
olanzapine
Clozapine
Cholinergic Agents
Risperidone
Cholinergic Antagonists
Cholinergic Agonists
Dopamine Agents
Cholinergic Receptors
Hypnotics and Sedatives
Population
Parkinson Disease
Dopamine
Alzheimer Disease
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Geriatrics and Gerontology

Cite this

Byerly, M. J., Weber, M. T., Brooks, D. L., Snow, L. R., Worley, M. A., & Lescouflair, E. (2001). Antipsychotic medications and the elderly: Effects on cognition and implications for use. Drugs and Aging, 18(1), 45-61.

Antipsychotic medications and the elderly : Effects on cognition and implications for use. / Byerly, M. J.; Weber, M. T.; Brooks, D. L.; Snow, L. R.; Worley, M. A.; Lescouflair, E.

In: Drugs and Aging, Vol. 18, No. 1, 2001, p. 45-61.

Research output: Contribution to journalArticle

Byerly, MJ, Weber, MT, Brooks, DL, Snow, LR, Worley, MA & Lescouflair, E 2001, 'Antipsychotic medications and the elderly: Effects on cognition and implications for use', Drugs and Aging, vol. 18, no. 1, pp. 45-61.
Byerly MJ, Weber MT, Brooks DL, Snow LR, Worley MA, Lescouflair E. Antipsychotic medications and the elderly: Effects on cognition and implications for use. Drugs and Aging. 2001;18(1):45-61.
Byerly, M. J. ; Weber, M. T. ; Brooks, D. L. ; Snow, L. R. ; Worley, M. A. ; Lescouflair, E. / Antipsychotic medications and the elderly : Effects on cognition and implications for use. In: Drugs and Aging. 2001 ; Vol. 18, No. 1. pp. 45-61.
@article{1289be2c170741f39c2885c23eb04f16,
title = "Antipsychotic medications and the elderly: Effects on cognition and implications for use",
abstract = "Despite being frequently prescribed in the elderly, antipsychotic medications are commonly associated with adverse effects in this population, including sedative, orthostatic and extrapyramidal adverse effects. Growing evidence suggests that antipsychotics can also cause deleterious cognitive effects in some elderly patients. Preclinical and growing clinical evidence indicates that inhibitory effects on dopaminergic, cholinergic and histaminergic neurochemical systems may account for antipsychotic-associated cognitive impairment in the elderly. A review of published reports of the cognitive effects of antipsychotics in the elderly suggests that newer antipsychotic medications may possess a more favourable cognitive profile than that of traditional agents in this population. The cognitive effect that a specific antipsychotic will have in the elderly, however, is likely better predicted by considering the pharmacodynamic action of an individual agent in combination with the pathophysiology of the condition being treated. Agents with relatively weak dopamine inhibiting effects (e.g. clozapine and quetiapine), for example, would theoretically have a cognitive profile superior to that of agents with higher degrees of dopaminergic inhibition (all traditional agents, risperidone, olanzapine and ziprasidone) when used for conditions associated with diminished dopamine function (e.g. idiopathic Parkinson's disease). Drugs with weak anticholinergic effects (high-potency traditional agents, risperidone, quetiapine and ziprasidone) would theoretically be less likely to cause cognitive impairment than agents with high degrees of cholinergic receptor blocking actions (clozapine and olanzapine) when treating patients with impaired cholinergic function (e.g. Alzheimer's disease). Cholinergic agonist effects of clozapine and olanzapine may, however, mitigate potential adverse cognitive effects associated with the cholinergic blocking actions of these agents. Large, rigorous trials comparing the cognitive effects of antipsychotics with diverse pharmacodynamic actions are lacking in the elderly and are needed.",
author = "Byerly, {M. J.} and Weber, {M. T.} and Brooks, {D. L.} and Snow, {L. R.} and Worley, {M. A.} and E. Lescouflair",
year = "2001",
language = "English (US)",
volume = "18",
pages = "45--61",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Antipsychotic medications and the elderly

T2 - Effects on cognition and implications for use

AU - Byerly, M. J.

AU - Weber, M. T.

AU - Brooks, D. L.

AU - Snow, L. R.

AU - Worley, M. A.

AU - Lescouflair, E.

PY - 2001

Y1 - 2001

N2 - Despite being frequently prescribed in the elderly, antipsychotic medications are commonly associated with adverse effects in this population, including sedative, orthostatic and extrapyramidal adverse effects. Growing evidence suggests that antipsychotics can also cause deleterious cognitive effects in some elderly patients. Preclinical and growing clinical evidence indicates that inhibitory effects on dopaminergic, cholinergic and histaminergic neurochemical systems may account for antipsychotic-associated cognitive impairment in the elderly. A review of published reports of the cognitive effects of antipsychotics in the elderly suggests that newer antipsychotic medications may possess a more favourable cognitive profile than that of traditional agents in this population. The cognitive effect that a specific antipsychotic will have in the elderly, however, is likely better predicted by considering the pharmacodynamic action of an individual agent in combination with the pathophysiology of the condition being treated. Agents with relatively weak dopamine inhibiting effects (e.g. clozapine and quetiapine), for example, would theoretically have a cognitive profile superior to that of agents with higher degrees of dopaminergic inhibition (all traditional agents, risperidone, olanzapine and ziprasidone) when used for conditions associated with diminished dopamine function (e.g. idiopathic Parkinson's disease). Drugs with weak anticholinergic effects (high-potency traditional agents, risperidone, quetiapine and ziprasidone) would theoretically be less likely to cause cognitive impairment than agents with high degrees of cholinergic receptor blocking actions (clozapine and olanzapine) when treating patients with impaired cholinergic function (e.g. Alzheimer's disease). Cholinergic agonist effects of clozapine and olanzapine may, however, mitigate potential adverse cognitive effects associated with the cholinergic blocking actions of these agents. Large, rigorous trials comparing the cognitive effects of antipsychotics with diverse pharmacodynamic actions are lacking in the elderly and are needed.

AB - Despite being frequently prescribed in the elderly, antipsychotic medications are commonly associated with adverse effects in this population, including sedative, orthostatic and extrapyramidal adverse effects. Growing evidence suggests that antipsychotics can also cause deleterious cognitive effects in some elderly patients. Preclinical and growing clinical evidence indicates that inhibitory effects on dopaminergic, cholinergic and histaminergic neurochemical systems may account for antipsychotic-associated cognitive impairment in the elderly. A review of published reports of the cognitive effects of antipsychotics in the elderly suggests that newer antipsychotic medications may possess a more favourable cognitive profile than that of traditional agents in this population. The cognitive effect that a specific antipsychotic will have in the elderly, however, is likely better predicted by considering the pharmacodynamic action of an individual agent in combination with the pathophysiology of the condition being treated. Agents with relatively weak dopamine inhibiting effects (e.g. clozapine and quetiapine), for example, would theoretically have a cognitive profile superior to that of agents with higher degrees of dopaminergic inhibition (all traditional agents, risperidone, olanzapine and ziprasidone) when used for conditions associated with diminished dopamine function (e.g. idiopathic Parkinson's disease). Drugs with weak anticholinergic effects (high-potency traditional agents, risperidone, quetiapine and ziprasidone) would theoretically be less likely to cause cognitive impairment than agents with high degrees of cholinergic receptor blocking actions (clozapine and olanzapine) when treating patients with impaired cholinergic function (e.g. Alzheimer's disease). Cholinergic agonist effects of clozapine and olanzapine may, however, mitigate potential adverse cognitive effects associated with the cholinergic blocking actions of these agents. Large, rigorous trials comparing the cognitive effects of antipsychotics with diverse pharmacodynamic actions are lacking in the elderly and are needed.

UR - http://www.scopus.com/inward/record.url?scp=0035115351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035115351&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 45

EP - 61

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 1

ER -